Stoke Therapeutics

About Stoke Therapeutics

Stoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA-based medicine. Their mission is to develop innovative therapies for severe genetic diseases by increasing protein output from healthy genes using their proprietary TANGO platform, aiming to address the underlying causes of conditions like Dravet syndrome.

Products & Services

TANGO Platform:A proprietary research platform (Targeted Augmentation of Nuclear Gene Output) that aims to restore missing proteins by increasing protein output from healthy genes, particularly for haploinsufficiencies and other severe diseases.

Zorevunersen (STK-001):A treatment in clinical studies for Dravet syndrome, intended as a disease-modifying therapy to address the genetic cause of this severe epilepsy.

Therapies for ADOA and SYNGAP1:Preclinical and exploratory therapies using TANGO ASOs to treat autosomal dominant optic atrophy (ADOA) and SYNGAP1-related disorders, targeting the underlying genetic causes.

Specialties

RNA-based medicine Genetic disease treatment Protein expression restoration Haploinsufficiency therapies Dravet syndrome treatment Autosomal dominant optic atrophy (ADOA) research SYNGAP1 disorder research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2024-03-27 FD: 2024-03-27	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: up to $75 million FAN: 75000000	D: 2024-03-26 FD: 2024-03-26	1 investors

Public Offering Latest

2024-03-27

$125.0M

1 investor (Pro only)

Public Offering 2024-03-26

$75.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Adrian Krainer

Professor

I

Isabel Aznarez

Co-Founder

LinkedIn (Pro only)

H

Huw Nash

Founding CEO

E

Edward M. Kaye

Director

I

Ian F. Smith

Chief Executive Officer & Director

J

Jonathan Allan

General Counsel

View 16 more team members with Pro

Unlock Full Team Directory

Recent News